When i asked on the board I think the consensus was the trial was over and no one was still receiving Kevetrin. This sure sounds like the patients were allowed to continue dosing, great news for the patients, who probably only had 3-6 months of survival, so I am assuming they are seeing benefits. God bless them!!
(1)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links